SCHEMBL396529

SCHEMBL396529

Cc1nccn1C#CCCc1nc2ccccc2o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
LOXL2 Q9Y4K0 1/20 0.46
PDE10A Q9Y233 2/20 0.43
TP53 P04637 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 1/20 0.41
GFER P55789 1/20 0.41
LMNA P02545 2/20 0.40
DRD3 P35462 5/20 0.38
DRD2 P14416 3/20 0.38
DRD4 P21917 2/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.36
ALOX15 P16050 1/20 0.36
USP2 O75604 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL103136 0.72 NPC1 (0.55) MAPTNPC1RAB9ALOXL2PDE10A
Hydrochloric Acid SCHEMBL103138 0.71 NPC1 (0.54) MAPTNPC1RAB9ALOXL2PDE10A
SCHEMBL103408 0.71 MAPT (0.50) MAPTNPC1RAB9ALOXL2PDE10A
SCHEMBL103977 0.71 MAPT (0.50) MAPTNPC1RAB9ALOXL2PDE10A
SCHEMBL155002 0.70 MAPT (1.00) MAPTNPC1RAB9ALOXL2PDE10A
SCHEMBL100737 0.70 MAPT (0.70) MAPTNPC1RAB9ALOXL2PDE10A
SCHEMBL102707 0.69 NPC1 (0.51) MAPTNPC1RAB9ALOXL2PDE10A
SCHEMBL396981 0.69 RAB9A (0.51) MAPTNPC1RAB9ALOXL2PDE10A
SCHEMBL102610 0.68 NPC1 (0.50) MAPTNPC1RAB9ALOXL2TP53
SCHEMBL103987 0.68 NPC1 (0.50) MAPTNPC1RAB9ALOXL2PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101637-B2 Alkynyl derivatives as modulators of metatropic glutamate receptors ADDEX PHARMA SA (CH) 2012-01-24 US disclosed
US-20090124625-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124625-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS GRM5, GRM2, GRM1 MAPT 630/4885NPC1 817/4885RAB9A 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.